Biotech entity
clinical-trial is the sole category represented across all 1 tracked stories. 177Lu rhPSMA‑10.1 Injection is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each carries 2 original sources on average. We currently track 1 Biotech story that mention University College London (UCL), all published on July 27, 2026.
Last mentioned: Jul 27, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
clinical-trial is the sole category represented across all 1 tracked stories. 177Lu rhPSMA‑10.1 Injection is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each carries 2 original sources on average. We currently track 1 Biotech story that mention University College London (UCL), all published on July 27, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 16 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering University College London (UCL). Shared-story counts are live from our verified record — not editorial picks.
First Participant Dosed
Blue Earth Therapeutics and UCL announced initiation of the Phase 1 trial (NCT07414940) with first participant receiving Actinium (225Ac) rhPSMA-10.1 Injection.
Blue Earth Therapeutics doses first patient in Phase 1 trial of actinium-225 rhPSMA-10.1 for mCRPC, aiming to assess safety and inform dose selection. The trial leverages PSMA targeting with high-energy alpha particles to kill cancer cells. Results could shape the next wave of radioligand therapies.
Source: prnewswire.com · finanznachrichten.de
University College London (UCL) is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
